Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, July 2, 2015, 72 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $300.62 to $7,318,309.60.

Highlighted Stocks Traded by Insiders:

Navidea Biopharmaceuticals (NAVB) - FREE Research Report

Larson Brent L, who is EVP, CFO, Treas and Sec'y at Navidea Biopharmaceuticals, sold 12,500 shares at $1.61 on July 2, 2015. Following this transaction, the EVP, CFO, Treas and Sec'y owned 284,737 shares meaning that the stake was reduced by 4.21% with the 12,500-share transaction.

The shares most recently traded at $1.68, up $0.07, or 4.12% since the insider transaction. Historical insider transactions for Navidea Biopharmaceuticals go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 12,500
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 25,000
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 45,000

The average volume for Navidea Biopharmaceuticals has been 470,200 shares per day over the past 30 days. Navidea Biopharmaceuticals has a market cap of $242.7 million and is part of the health care sector and drugs industry. Shares are down 14.29% year-to-date as of the close of trading on Wednesday.

Navidea Biopharmaceuticals, Inc., a precision medicine company, focuses on the development and commercialization of precision diagnostics, therapeutics, and radiopharmaceutical agents. Currently, there is 1 analyst who rates Navidea Biopharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NAVB - FREE

TheStreet Quant Ratings

rates Navidea Biopharmaceuticals as a

sell

. The area that we feel has been the company's primary weakness has been its unimpressive growth in net income. Get the full

Navidea Biopharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

State Auto Financial (STFC) - FREE Research Report

State Automobile Mutual Insurance Co, who is 10% Owner at State Auto Financial, bought 2,500 shares at $24.31 on July 2, 2015. Following this transaction, the 10% Owner owned 25.9 million shares meaning that the stake was boosted by 0.01% with the 2,500-share transaction.

The shares most recently traded at $25.26, up $0.95, or 3.77% since the insider transaction. Historical insider transactions for State Auto Financial go as follows:

  • 4-Week # shares bought: 300
  • 12-Week # shares bought: 73,493
  • 24-Week # shares bought: 219,400

The average volume for State Auto Financial has been 34,300 shares per day over the past 30 days. State Auto Financial has a market cap of $984.9 million and is part of the financial sector and insurance industry. Shares are up 10.62% year-to-date as of the close of trading on Wednesday.

State Auto Financial Corporation, through its subsidiaries, engages in writing personal, business, and specialty insurance products. It operates through four segments: Personal insurance, Business insurance, Specialty insurance, and Investment operations. The stock currently has a dividend yield of 1.67%. The company has a P/E ratio of 9.4. Currently, there is 1 analyst who rates State Auto Financial a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on STFC - FREE

TheStreet Quant Ratings

rates State Auto Financial as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, good cash flow from operations and notable return on equity. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

State Auto Financial Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Chemed (CHE) - FREE Research Report

Krebs Walter L, who is Director at Chemed, sold 5,000 shares at $132.04 on July 2, 2015. Following this transaction, the Director owned 10,823 shares meaning that the stake was reduced by 31.6% with the 5,000-share transaction.

The shares most recently traded at $130.99, down $1.05, or 0.8% since the insider transaction. Historical insider transactions for Chemed go as follows:

  • 4-Week # shares sold: 400
  • 12-Week # shares sold: 5,905
  • 24-Week # shares sold: 39,529

The average volume for Chemed has been 128,000 shares per day over the past 30 days. Chemed has a market cap of $2.2 billion and is part of the health care sector and health services industry. Shares are up 25.8% year-to-date as of the close of trading on Wednesday.

Chemed Corporation provides hospice and palliative care services in the United States. It operates in two segments, VITAS and Roto-Rooter. The company offers its services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers. The stock currently has a dividend yield of 0.67%. The company has a P/E ratio of 22.4. Currently, there is 1 analyst who rates Chemed a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on CHE - FREE

TheStreet Quant Ratings

rates Chemed as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full

Chemed Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.